Mark Lazari1, Jeffrey Collins2, Bin Shen3, Mohammed Farhoud4, Daniel Yeh5, Brandon Maraglia6, Frederick T Chin3, David A Nathanson5, Melissa Moore6, R Michael van Dam7. 1. Department of Bioengineering, Henry Samueli School of Engineering, UCLA, Los Angeles, California Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California Crump Institute for Molecular Imaging, David Geffen School of Medicine, UCLA, Los Angeles, California. 2. Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California Crump Institute for Molecular Imaging, David Geffen School of Medicine, UCLA, Los Angeles, California. 3. Molecular Imaging Program at Stanford (MIPS) Department of Radiology, Stanford University, Stanford, California. 4. Sofie Biosciences, Inc., Culver City, California; and. 5. Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California Ahmanson Translational Imaging Division, David Geffen School of Medicine, UCLA, Los Angeles, California. 6. Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California Crump Institute for Molecular Imaging, David Geffen School of Medicine, UCLA, Los Angeles, California Sofie Biosciences, Inc., Culver City, California; and. 7. Department of Bioengineering, Henry Samueli School of Engineering, UCLA, Los Angeles, California Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California Crump Institute for Molecular Imaging, David Geffen School of Medicine, UCLA, Los Angeles, California mvandam@mednet.ucla.edu.
Abstract
UNLABELLED: Fully automated radiosynthesizers are continuing to be developed to meet the growing need for the reliable production of PET tracers made under current good manufacturing practice guidelines. There is a current trend toward supporting kitlike disposable cassettes that come preconfigured for particular tracers, thus eliminating the need for cleaning protocols between syntheses and enabling quick transitions to synthesizing other tracers. Though ideal for production, these systems are often limited for the development of novel tracers because of pressure, temperature, and chemical compatibility considerations. This study demonstrated the versatile use of the ELIXYS fully automated radiosynthesizer to adapt and produce 8 different (18)F-labeled PET tracers of varying complexity. METHODS: Three-reactor syntheses of 2-deoxy-2-(18)F-fluoro-β-d-arabinofuranosylcytosine (d-(18)F-FAC), 2-deoxy-2-(18)F-fluoro-5-methyl-β-l-arabinofuranosyluracil (l-(18)F-FMAU), and 2-deoxy-2-(18)F-fluoro-5-ethyl-β-d-arabinofuranosyluracil (d-(18)F-FEAU) along with the 1-reactor syntheses of d-(18)F-FEAU, (18)F-FDG, 3-deoxy-3-(18)F-fluoro-l-thymidine ((18)F-FLT), (18)F-fallypride, 9-(4-(18)F-fluoro-3-hydroxymethylbutyl)-guanine ((18)F-FHBG), and N-succinimidyl-4-(18)F-fluorobenzoate ((18)F-SFB), were all produced using ELIXYS without the need for any hardware modifications or reconfiguration. Synthesis protocols were adapted and slightly modified from those in the literature but were not fully optimized. Furthermore, (18)F-FLT, (18)F-FDG, and (18)F-fallypride were produced sequentially on the same day and used for preclinical imaging of A431 tumor-bearing severe combined immunodeficient mice and wild-type BALB/c mice. To assess future translation to the clinical setting, several batches of tracers were subjected to a full set of quality control tests. RESULTS: All tracers were produced with radiochemical yields comparable to those in the literature. (18)F-FLT, (18)F-FDG, and (18)F-fallypride were successfully used to image the mice, with results consistent with those reported in the literature. All tracers that were subjected to clinical quality control tests passed. CONCLUSION: The ELIXYS radiosynthesizer facilitates rapid tracer development and is capable of producing multiple (18)F-labeled PET tracers suitable for clinical applications using the same hardware setup.
UNLABELLED: Fully automated radiosynthesizers are continuing to be developed to meet the growing need for the reliable production of PET tracers made under current good manufacturing practice guidelines. There is a current trend toward supporting kitlike disposable cassettes that come preconfigured for particular tracers, thus eliminating the need for cleaning protocols between syntheses and enabling quick transitions to synthesizing other tracers. Though ideal for production, these systems are often limited for the development of novel tracers because of pressure, temperature, and chemical compatibility considerations. This study demonstrated the versatile use of the ELIXYS fully automated radiosynthesizer to adapt and produce 8 different (18)F-labeled PET tracers of varying complexity. METHODS: Three-reactor syntheses of 2-deoxy-2-(18)F-fluoro-β-d-arabinofuranosylcytosine (d-(18)F-FAC), 2-deoxy-2-(18)F-fluoro-5-methyl-β-l-arabinofuranosyluracil (l-(18)F-FMAU), and 2-deoxy-2-(18)F-fluoro-5-ethyl-β-d-arabinofuranosyluracil (d-(18)F-FEAU) along with the 1-reactor syntheses of d-(18)F-FEAU, (18)F-FDG, 3-deoxy-3-(18)F-fluoro-l-thymidine ((18)F-FLT), (18)F-fallypride, 9-(4-(18)F-fluoro-3-hydroxymethylbutyl)-guanine ((18)F-FHBG), and N-succinimidyl-4-(18)F-fluorobenzoate ((18)F-SFB), were all produced using ELIXYS without the need for any hardware modifications or reconfiguration. Synthesis protocols were adapted and slightly modified from those in the literature but were not fully optimized. Furthermore, (18)F-FLT, (18)F-FDG, and (18)F-fallypride were produced sequentially on the same day and used for preclinical imaging of A431tumor-bearing severe combined immunodeficientmice and wild-type BALB/c mice. To assess future translation to the clinical setting, several batches of tracers were subjected to a full set of quality control tests. RESULTS: All tracers were produced with radiochemical yields comparable to those in the literature. (18)F-FLT, (18)F-FDG, and (18)F-fallypride were successfully used to image the mice, with results consistent with those reported in the literature. All tracers that were subjected to clinical quality control tests passed. CONCLUSION: The ELIXYS radiosynthesizer facilitates rapid tracer development and is capable of producing multiple (18)F-labeled PET tracers suitable for clinical applications using the same hardware setup.
Authors: Bernard Amaraesekera; Phillip D Marchis; Krzysztof P Bobinski; Caius G Radu; Johannes Czernin; Jorge R Barrio; R Michael van Dam Journal: Appl Radiat Isot Date: 2013-04-25 Impact factor: 1.513
Authors: Mark Lazari; Serge K Lyashchenko; Eva M Burnazi; Jason S Lewis; R Michael van Dam; Jennifer M Murphy Journal: Appl Radiat Isot Date: 2015-05-21 Impact factor: 1.513
Authors: Philip H Chao; Jeffery Collins; Joseph P Argus; Wei-Yu Tseng; Jason T Lee; R Michael van Dam Journal: Lab Chip Date: 2017-05-16 Impact factor: 6.799
Authors: Maxim E Sergeev; Mark Lazari; Federica Morgia; Jeffrey Collins; Muhammad Rashed Javed; Olga Sergeeva; Jason Jones; Michael E Phelps; Jason T Lee; Pei Yuin Keng; R Michael van Dam Journal: Commun Chem Date: 2018-03-22
Authors: Hayden T Ravert; Daniel P Holt; Ying Chen; Ronnie C Mease; Hong Fan; Martin G Pomper; Robert F Dannals Journal: J Labelled Comp Radiopharm Date: 2016-07-29 Impact factor: 1.921
Authors: Tobey J Betthauser; Paul A Ellison; Dhanabalan Murali; Patrick J Lao; Todd E Barnhart; Shozo Furumoto; Nobuyuki Okamura; Sterling C Johnson; Jonathan W Engle; Robert J Nickles; Bradley T Christian Journal: Appl Radiat Isot Date: 2017-10-04 Impact factor: 1.513
Authors: Jeffrey Collins; Christopher M Waldmann; Christopher Drake; Roger Slavik; Noel S Ha; Maxim Sergeev; Mark Lazari; Bin Shen; Frederick T Chin; Melissa Moore; Saman Sadeghi; Michael E Phelps; Jennifer M Murphy; R Michael van Dam Journal: Proc Natl Acad Sci U S A Date: 2017-10-10 Impact factor: 11.205
Authors: Maxim E Sergeev; Federica Morgia; Mark Lazari; Christopher Wang; R Michael van Dam Journal: J Am Chem Soc Date: 2015-04-22 Impact factor: 15.419
Authors: Christopher M Waldmann; Adrian Gomez; Phillip Marchis; Sean T Bailey; Milica Momcilovic; Anthony E Jones; David B Shackelford; Saman Sadeghi Journal: Mol Imaging Biol Date: 2018-04 Impact factor: 3.488